CORRESPONDENCE RESPONSE

BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors by M Genovese We read with great interest the article by Genovese et al1 on the effect of the B-cell activating factor (BAFF) antagonist tabalu-mab in rheumatoid arthritis patients with inadequate response to tumour necrosis factor (TNF)a blockade. The results of this study indicated a moderate effect of tabalumab early (week 6/week 9) after ini-tiation of therapy, both in terms of clinical as well as laboratory markers of diseas